KRAS inhibitors

Merck's early KRAS data suggest combination-friendly safety
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
Flag link:
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Amgen
Lumakras
FDA
KRAS inhibitors
Flag link:
Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase
Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase
Fierce Pharma
Mirati Therapeutics
Sanofi
M&A
KRAS inhibitors
Flag link:
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
BioSpace
Roche
Genentech
divarasib
KRAS inhibitors
solid tumors
clinical trials
Flag link:
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
Fierce Pharma
Amgen
Lumakras
KRAS inhibitors
FDA
Flag link:
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
BioSpace
Mirati Therapeutics
Pharma CEOs
David Meek
Amgen
KRAS inhibitors
Flag link:
In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets
In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets
Pharma Voice
Affini-T Therapeutics
oncology
KRAS inhibitors
Flag link:
AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'
AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'
Fierce Biotech
Eli Lilly
Amgen
Mirati Therapeutics
KRAS inhibitors
AACR
Flag link:
ESMO 2022 movers – KRAS backfires
ESMO 2022 movers – KRAS backfires
EP Vantage
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Flag link:
ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames
ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames
Fierce Pharma
Amgen
lung cancer
ESMO
KRAS inhibitors
Flag link:
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Fierce Biotech
Genentech
Relay Therapeutics
Roche
KRAS inhibitors
Flag link:
Eli Lilly crashes out of KRAS race as toxicity sees it ditch phase 1 effort
Eli Lilly crashes out of KRAS race as toxicity sees it ditch phase 1 effort
Fierce Biotech
Eli Lilly
KRAS inhibitors
cancer
Flag link:
Researchers Develop New Class of Lung Cancer Drugs
Researchers Develop New Class of Lung Cancer Drugs
BioSpace
lung cancer
KRAS inhibitors
Institute of Cancer Research
drug development
Flag link:
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
Biopharma Dive
Amgen
AMG 510
KRAS inhibitors
Roche
PTC Therapeutics
risdiplam
Eylea
Novartis
Flag link:
Here's Why Mirati Therapeutics Is Surging Today
Here's Why Mirati Therapeutics Is Surging Today
Motley Fool
Mirati Therapeutics
Amgen
KRAS inhibitors
MRTX849
AMG 510
Flag link: